This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Lipid-lowering therapy versus coronary angioplasty

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • this was a randomised controlled, blinded trial with 18 months follow-up
  • 341 patients were recruited who had been recommended for percutaneous transluminal coronary angioplasty (PTCA) who had stable coronary heart disease (CHD) - 177 patients were allocated to PTCA and 164 were allocated to atorvastatin, 80 mg per day
  • patients were excluded if they had left main coronary artery disease, triple vessel disease, ejection fraction of less than 40%, or recent myocardial infarction or unstable angina. There was a 100% follow-up
  • this trial revealed that treatment with atorvastatin was at least as effective as PTCA plus usual care as a means of reducing ischaemic events in patients with stable CHD. There was evidence that PTCA offered better symptom control


Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page